Defining disease status in gastroenteropancreatic neuroendocrine tumors: Choi-criteria or RECIST?

Mark J C van TreijenJ M H SchoeversB C HeeresD van der ZeeM MaasG D ValkM E T Tesselaar

Published in: Abdominal radiology (New York) (2022)

RECIST v1.1 had a better clinical utility and prognostic value compared to Choi-criteria. Still, RECIST were also not sufficient to adequately predict OS. This outlines the need for new tools that provides accurate information on the disease course and treatment response to support precise prognostication in patients with GEP-NETs.

Keyphrases

neuroendocrine tumors
high resolution
health information
combination therapy
social media
replacement therapy